Lung cancer is a public health priority worldwide due to the high mortality rate and the costs involved .
In recent years serum biomarkers have been proposed as a method that might enhance diagnostic capabilities and complement imaging studies .
However , it has become clear that a universal biomarker panel does not exist , and optimized panels need to be developed and validated in each population before their application in a clinical setting .
Principal component analysis and artificial neural network modeling allowed us to find a reduced biomarker panel composed of Cyfra 21.1 , CEA , CA125 and CRP .

